HC Wainwright reaffirmed their buy rating on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a report published on Friday. The firm currently has a $12.00 price target on the biotechnology company’s stock.
Other equities analysts also recently issued research reports about the stock. ValuEngine upgraded shares of Pieris Pharmaceuticals from a sell rating to a hold rating in a report on Friday, February 2nd. BidaskClub cut shares of Pieris Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Saturday, February 17th. Finally, William Blair started coverage on shares of Pieris Pharmaceuticals in a research note on Wednesday, January 17th. They set an outperform rating on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $10.00.
Pieris Pharmaceuticals (NASDAQ PIRS) opened at $7.67 on Friday. Pieris Pharmaceuticals has a fifty-two week low of $2.26 and a fifty-two week high of $9.75. The firm has a market cap of $343.57, a P/E ratio of -10.51 and a beta of -66.74.
Several hedge funds and other institutional investors have recently modified their holdings of PIRS. Schwab Charles Investment Management Inc. acquired a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth approximately $292,000. Teachers Advisors LLC acquired a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth approximately $308,000. TIAA CREF Investment Management LLC acquired a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth approximately $649,000. Northern Trust Corp acquired a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth approximately $1,625,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth approximately $526,000. 47.19% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Pieris Pharmaceuticals (PIRS) Receives Buy Rating from HC Wainwright” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://sportsperspectives.com/2018/03/13/pieris-pharmaceuticals-pirs-receives-buy-rating-from-hc-wainwright.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.